RECEIVED CENTRAL FAX CENTER

OCT 08 2004

fle purpose only

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ming-Hui WEI et al.

Art Unit: 1652

Serial No.: 10/681,223

Examiner: M. Monshipouri

Filed: October 9, 2003

Atty. Docket: CL001305DIV2

For: ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES

THEREOF

PRELIMINARY AMENDMENT

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231 By Facsimile

Sir:

This is in response to an Office Action mailed on September 8, 2004 from Examiner Monshipouri in which a restriction requirement was issued for the above-referenced application.

Applicants hereby elect claim group III (claims 4-6, 8-11, and 22-23, drawn to isolated nucleic acid molecules, vectors, host cells, etc.) for examination and have canceled claims corresponding to the non-elected groups I-II and IV-VIII.

Please amend the application as follows:

10/20/2004 DUILLIG4 00000003 560970 | websites

01 FER1202 02 FER1203 120,00 MD

ACCOUNTAGELITY

DEPOSIT ACCOUNT NO.

SO 0970

FEE VALUE
COLVE FURNISHED

1202 59490

203 30000

Serial No. 10/681,223

REMARKS

By way of the above amendments, claims 1-23 have been canceled, and claims 24-37 have been added. As such, claims 24-37 are presently pending.

The newly added claims add no new subject matter and their entry is respectfully requested.

Applicants respectfully assert that the claims are in condition for examination on the merits.

Respectfully submitted,

CELERA GENOMICS

By: 🤇

Justin D. Karfala Reg. No. 43,704

Date: October 8, 2004

Celera Genomics Corporation 45 West Gude Drive, C2-4#20 Rockville, MD 20850 Tel: 240-453-3812

Fax: 240-453-3084

Application No.: 10/681,223

Examiner: Maryam MONSHIPOURI

Filed: October 9, 2003

Group Art Unit: 1652

Inventor: Ming-Hui WEI

Attorney Docket No.: CL001305DIV-II

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment in the above-identified application.

No additional fee is required.

The fee has been calculated as shown below:

		C	LAIMS AS AMENI	DED	•	
	TOTAL CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL CLAIMS	56	MINUS	23	33	x \$18	\$ 594.00
INDEP. CLAIMS	6	MINUS	. 6	= 0	x \$88	\$ 0.00
Fee for Mu	iltiple Dependent cla	ims= \$300				\$300.00
			TOTAL ADDITION FOR THIS AMEND			\$ 894.00

Verified Statement claiming sma	ill entity status is enclosed, if not filed p	meviously.
		_

\Box	A check in the amount of \$	is enclosed

Charge the amount of \$894.00 to Deposit Account No. 50-0970 to cover the additional claims fee. A duplicate copy of this sheet is enclosed.

	Any prior general authorization to charge an issue fee under 37 C.F.R. § 1.18 to Deposit Account No. 50-0970 is hereby revoked. The Commissioner is hereby authorized to charge any additional fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required during the entire pendency of this application, or to credit any overpayment, to Deposit Account No. 50-0970. A duplicate copy of this paper is enclosed.		
	Charge the amount of \$_ to Deposit Account No. 50-0970 to cover the Extension fee for response within months. A duplicate copy of this sheet is enclosed.		
	Charge the amount of \$ to Deposit Account No. 50-0970 to cover the Information Disclosure Statement fee. A duplicate copy of this sheet is enclosed.		
	Respectfully submitted,		
	CELERA GENOMICS		
•	By:		
•	Reg No. 43 704		

Date: October 8, 2004

Celera Genomics Corporation 45 West Gude Drive, C1-1#316 Rockville, MD 20850

Tel: 240-453-3812 Fax: 240-453-3084